Keyword: Fresenius Medical Care
In the wake of Hurricane Michael, the two largest dialysis companies in the country have opened their doors to all patients seeking treatment.
Fresenius signed a $150 million global commercialization deal with Humacyte for its regenerative blood vessel implant and bought 19% of the company.
Vifor Pharma and Fresenius acquired a global license to commercialize Cara Therapeutics’ Korsuva for intense itching associated with CKD and dialysis.
The pharmacy chain will start a clinical trial later this year with a view to securing FDA approval and offering an at-home dialysis service by 2020.
Tyagi joins Hikma with a brief to stimulate noninjectable R&D activity at a time when the company's generic drug unit is suffering.
The takeover will bolster Fresenius’ at-home dialysis unit, positioning it to profit if patients opt against receiving treatment in its care centers.
PPD just formed a partnership with Frenova Renal Research, which is giving PPD access to its vast network of nephrology experts and patients.
The FDA cleared Fresenius Kabi’s plasma collection system that accelerates the plasma collection process, facilitating plasma donation for donors and center operators alike.